Selecting treatment options in refractory metastatic colorectal cancer

Selecting treatment options in refractory metastatic colorectal cancer

Margaret Byrne, Muhammad Wasif Saif Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, NY, USA Abstract: Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven...

Full description

Bibliographic Details
Main Authors: Byrne M, Saif MW
Format: Article
Language:English
Published: Dove Medical Press 2019-03-01
Series:OncoTargets and Therapy
Subjects:
TKI
fluoropyrimidine
bevacizumab
cetuximab
panitumumab
PD-1 inhibitor
FOLFIRI
epidermal growth factor receptor
vascular endothelial growth factor receptor
platelet-derived growth factor receptors
KRAS
NRAS
HER2
advanced
colon cancer
refractory
lonsurf
regorafenib
Online Access:https://www.dovepress.com/selecting-treatment-options-in-refractory-metastatic-colorectal-cancer-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/selecting-treatment-options-in-refractory-metastatic-colorectal-cancer-peer-reviewed-article-OTT

Similar Items